4//SEC Filing
Cline Christopher R. 4
Accession 0001415889-24-023091
CIK 0001438533other
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 9:20 PM ET
Size
7.4 KB
Accession
0001415889-24-023091
Insider Transaction Report
Form 4
Cline Christopher R.
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2024-09-09$11.52/sh−2,490$28,685→ 74,595 total - Award
Common Stock
2024-09-05+6,750→ 77,085 total
Footnotes (2)
- [F1]On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
- [F2]Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested performance restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001943192
Filing Metadata
- Form type
- 4
- Filed
- Sep 8, 8:00 PM ET
- Accepted
- Sep 9, 9:20 PM ET
- Size
- 7.4 KB